Lixisenatide is currently undergoing phase III GetGoal clinical trial programme, which is expected to be completed in the second quarter of 2011.
-
Lixisenatide is a new GLP-1 class drug for type 2 diabetes treatment. -
Type 2 diabetes affects more than 90% to 95% of diabetes patients. -
Lixisenatide works by controlling blood sugar by increasing the production of... -
Lixisenatide is currently undergoing phase III GetGoal clinical trial...
